axatilimab   Click here for help

GtoPdb Ligand ID: 13497

Synonyms: Ab969 [US9908939] | axatilimab-csfr | INCA034176 | Niktimvo® | SNDX-6352 | UCB-6352
Approved drug
axatilimab is an approved drug
Compound class: Antibody
Comment: Axatilimab (SNDX-6352, formerly UCB-6352) is a humanized anti-CSF-1R antibody. It was initially developed as an alternative therapeutic modality for the treatment of chronic graft-versus-host disease (GvHD) [3]. Axatilimab targets macrophage-mediated inflammation and fibrosis that cause organ damage in GvHD, by blocking CSF-1R activation by either of its ligands (CSF-1 and IL-34).
Peptide sequences from the axatilimab INN entry align with sequences that are claimed in a UCB Biopharma patent originally filed in 2014 [1].
Click here for help
No information available.
Summary of Clinical Use Click here for help
The FDA approved axatilimab in August 2024, as a third-line treatment for (refractory) chronic graft-versus-host disease (GvHD) after failure of two prior systemic therapies [2]. Clinical trials were progressed to evaluate axatilimab efficacy in other diseases, including idiopathic pulmonary fibrosis (IPF) and advanced cancers. Development for IPF was discontinued in fall 2026, due to lack of efficacy in phase 2.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04710576 A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) Phase 2 Interventional Syndax Pharmaceuticals FDA approval was based on positive safety and efficacy outcomes from this (AGAVE-201) study.
NCT05723055 Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Phase 2 Interventional University of Utah
NCT06132256 Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Phase 2 Interventional Syndax Pharmaceuticals
NCT06388564 A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease Phase 2 Interventional Incyte Corporation